Clopidogrel - Hanmi Pharmaceutical

Drug Profile

Clopidogrel - Hanmi Pharmaceutical

Alternative Names: Clopidogrel napadisilate; Clopidogrel napadisilate monohydrate; Pidogul

Latest Information Update: 13 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Myocardial infarction; Peripheral arterial disorders; Stroke

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Jan 2012 Hanmi Pharmaceutical's Clopidogrel product is available for market licensing in European Union as of 10 Jan 2012.
  • 10 Jan 2012 Registered for Acute coronary syndromes in Cyprus (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top